NCT04560465

Brief Summary

to determine safety and efficacy of Tranexamic Acid in reducing blood loss during Myomectomy in our institution.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
59

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jun 2018

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2019

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

September 18, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 23, 2020

Completed
Last Updated

September 23, 2020

Status Verified

September 1, 2020

Enrollment Period

12 months

First QC Date

September 18, 2020

Last Update Submit

September 18, 2020

Conditions

Keywords

Tranexamic acid, Myomectomy, Blood loss, Gravimetric

Outcome Measures

Primary Outcomes (3)

  • Average duration of surgery in each group

    Average duration of Surgeries were calculated for each group

    one year

  • Mean intraoperative Blood loss

    The mean intraoperative blood loss was calculated for both groups

    one year

  • Postoperative Haemoglobin concentration

    Average Postoperative Haemoglobin concentration of both groups were determined

    one year

Secondary Outcomes (1)

  • Blood Transfusion

    One year

Study Arms (2)

group A: Cases that had tranexamic acid infusion

EXPERIMENTAL

Group A had perioperative tranexamic acid infusion at the rate of 100mls per hour

Drug: Tranexamic acid

Group B: Control

PLACEBO COMPARATOR

control were given perioperative placebo at the rate of 100mls per hour

Drug: Tranexamic acid

Interventions

intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control

Group B: Controlgroup A: Cases that had tranexamic acid infusion

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • non-pregnant women with symptomatic myomas women with no known contraindication to tranexamic acid

You may not qualify if:

  • past history of thromboembolic disorder, ischaemic heart disease, malignancy or liver disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AEFUTHA

Abakaliki, Ebonyi State, 480213, Nigeria

Location

Related Publications (1)

  • Olaleye AA, Adebayo JA, Eze JN, Ajah LO, Anikwe CC, Egede JO, Ebere CI. Efficacy of Tranexamic Acid in Reducing Myomectomy-Associated Blood Loss among Patients with Uterine Myomas at Federal Teaching Hospital Abakaliki: A Randomized Control Trial. Int J Reprod Med. 2024 Jan 18;2024:2794052. doi: 10.1155/2024/2794052. eCollection 2024.

MeSH Terms

Conditions

Hemorrhage

Interventions

Tranexamic Acid

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Masking Details
double blind
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: two groups comprising of cases and control
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

September 18, 2020

First Posted

September 23, 2020

Study Start

June 1, 2018

Primary Completion

May 31, 2019

Study Completion

June 1, 2019

Last Updated

September 23, 2020

Record last verified: 2020-09

Locations